252 related articles for article (PubMed ID: 26931080)
1. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
Mullard A
Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
[No Abstract] [Full Text] [Related]
2. A BH3 Mimetic for Killing Cancer Cells.
Green DR
Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
[TBL] [Abstract][Full Text] [Related]
3. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
[No Abstract] [Full Text] [Related]
4. Suzanne Cory: Life-and-Death Switches: the Rise of BH3 Mimetics.
Trends Cancer; 2016 Oct; 2(10):537-539. PubMed ID: 28741484
[No Abstract] [Full Text] [Related]
5. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
6. Regulation of Apoptosis by the Bcl-2 Family of Proteins: Field on a Brink.
Ladokhin AS
Cells; 2020 Sep; 9(9):. PubMed ID: 32961920
[TBL] [Abstract][Full Text] [Related]
7. Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies.
Roberts AW; Huang D
Clin Pharmacol Ther; 2017 Jan; 101(1):89-98. PubMed ID: 27806433
[TBL] [Abstract][Full Text] [Related]
8. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
[TBL] [Abstract][Full Text] [Related]
9. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
10. Therapeutic inhibition of BCL-2 and related family members.
Levy MA; Claxton DF
Expert Opin Investig Drugs; 2017 Mar; 26(3):293-301. PubMed ID: 28161988
[TBL] [Abstract][Full Text] [Related]
11. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
Cang S; Iragavarapu C; Savooji J; Song Y; Liu D
J Hematol Oncol; 2015 Nov; 8():129. PubMed ID: 26589495
[TBL] [Abstract][Full Text] [Related]
12. Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.
Yalniz FF; Wierda WG
Drugs; 2019 Aug; 79(12):1287-1304. PubMed ID: 31313099
[TBL] [Abstract][Full Text] [Related]
13. BCL-2: Long and winding path from discovery to therapeutic target.
Schenk RL; Strasser A; Dewson G
Biochem Biophys Res Commun; 2017 Jan; 482(3):459-469. PubMed ID: 28212732
[TBL] [Abstract][Full Text] [Related]
14. Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer.
Merino D; Lok SW; Visvader JE; Lindeman GJ
Oncogene; 2016 Apr; 35(15):1877-87. PubMed ID: 26257067
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA Dysregulation to Identify Novel Therapeutic Targets.
Croce CM
Curr Top Microbiol Immunol; 2017; 407():191-203. PubMed ID: 28653191
[TBL] [Abstract][Full Text] [Related]
16. The BCL-2 arbiters of apoptosis and their growing role as cancer targets.
Adams JM; Cory S
Cell Death Differ; 2018 Jan; 25(1):27-36. PubMed ID: 29099483
[TBL] [Abstract][Full Text] [Related]
17. Menin inhibition decreases Bcl-2 and synergizes with venetoclax in NPM1/FLT3-mutated AML.
Carter BZ; Tao W; Mak PY; Ostermann LB; Mak D; McGeehan G; Ordentlich P; Andreeff M
Blood; 2021 Oct; 138(17):1637-1641. PubMed ID: 34232981
[No Abstract] [Full Text] [Related]
18. Therapeutic development and current uses of BCL-2 inhibition.
Roberts AW
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):1-9. PubMed ID: 33275682
[TBL] [Abstract][Full Text] [Related]
19. BCL2 blockade overcomes MCL1 resistance in multiple myeloma.
Siu KT; Huang C; Panaroni C; Mukaihara K; Fulzele K; Soucy R; Thorburn C; Cidado J; Drew L; Chattopadhyay S; Raje N
Leukemia; 2019 Aug; 33(8):2098-2102. PubMed ID: 30816329
[No Abstract] [Full Text] [Related]
20. Targeting MCL1, Companies Aim to Unblock Apoptosis.
Cancer Discov; 2019 May; 9(5):572. PubMed ID: 30944116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]